SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-12-044168
Filing Date
2012-08-09
Accepted
2012-08-09 17:26:44
Documents
11
Period of Report
2012-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q v318815_10q.htm 10-Q 352466
2 EXHIBIT 31.1 v318815_ex31-1.htm EX-31.1 7823
3 EXHIBIT 31.2 v318815_ex31-2.htm EX-31.2 7886
4 EXHIBIT 32.1 v318815_ex32-1.htm EX-32.1 3721
5 EXHIBIT 32.2 v318815_ex32-2.htm EX-32.2 3629
  Complete submission text file 0001144204-12-044168.txt   3424974

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT navb-20120630.xml EX-101.INS 319743
8 XBRL TAXONOMY EXTENSION SCHEMA navb-20120630.xsd EX-101.SCH 49518
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20120630_cal.xml EX-101.CAL 57118
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20120630_def.xml EX-101.DEF 260553
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20120630_lab.xml EX-101.LAB 382945
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20120630_pre.xml EX-101.PRE 304885
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 121021673
SIC: 2835 In Vitro & In Vivo Diagnostic Substances